Sanofi acquires Vicebio for $1.15 billion, adding a next-gen RSV-hMPV vaccine and ‘Molecular Clamp' tech to strengthen its respiratory vaccine pipeline.

The new guidance on vaccines, such as those that protect against COVID-19, influenza, and RSV, will be released by the end of the summer, ahead of respiratory season.